Smoothened variants explain the majority of drug resistance in basal cell carcinoma.

abstract：:Expression of the cyclin-dependent kinase inhibitor p27(Kip1) (p27) is frequently reduced in human colorectal cancer, and this correlates with poor patient prognosis. To clarify the role of p27 in gastrointestinal (GI) cancer, we measured p27 expression, as well as the effect of germline deletion of p27, in 3 differen...

journal_title：Cancer cell

authors： Philipp-Staheli J,Kim KH,Payne SR,Gurley KE,Liggitt D,Longton G,Kemp CJ

更新日期：2002-05-01 00:00:00

abstract：:Metastasis and therapy resistance are cardinal features of pancreatic ductal adenocarcinoma, a commonly lethal malignancy. In this issue of Cancer Cell, Steele et al. show that CXCR2 expression and neutrophils are required for metastasis. In mice treated with advanced disease, inhibiting both CXCR2 and PD1 cooperative...

journal_title：Cancer cell

authors： Stromnes IM,Greenberg PD

更新日期：2016-06-13 00:00:00

abstract：:We characterized the landscape and drug sensitivity of ERBB2 (HER2) mutations in cancers. In 11 datasets (n = 211,726), ERBB2 mutational hotspots varied across 25 tumor types. Common HER2 mutants yielded differential sensitivities to eleven EGFR/HER2 tyrosine kinase inhibitors (TKIs) in vitro, and molecular dynamics s...

journal_title：Cancer cell

authors： Robichaux JP,Elamin YY,Vijayan RSK,Nilsson MB,Hu L,He J,Zhang F,Pisegna M,Poteete A,Sun H,Li S,Chen T,Han H,Negrao MV,Ahnert JR,Diao L,Wang J,Le X,Meric-Bernstam F,Routbort M,Roeck B,Yang Z,Raymond VM,Lanman

更新日期：2019-10-14 00:00:00

abstract：:Single-cell sequencing (SCS) has impacted many areas of cancer research and improved our understanding of intratumor heterogeneity, the tumor microenvironment, metastasis, and therapeutic resistance. The development and refinement of SCS technologies has led to massive reductions in costs, increased cell throughput, a...

journal_title：Cancer cell

authors： Lim B,Lin Y,Navin N

更新日期：2020-04-13 00:00:00

abstract：:The EZH2 histone methyltransferase mediates the humoral immune response and drives lymphomagenesis through formation of bivalent chromatin domains at critical germinal center (GC) B cell promoters. Herein we show that the actions of EZH2 in driving GC formation and lymphoma precursor lesions require site-specific bind...

journal_title：Cancer cell

authors： Béguelin W,Teater M,Gearhart MD,Calvo Fernández MT,Goldstein RL,Cárdenas MG,Hatzi K,Rosen M,Shen H,Corcoran CM,Hamline MY,Gascoyne RD,Levine RL,Abdel-Wahab O,Licht JD,Shaknovich R,Elemento O,Bardwell VJ,Melnick AM

更新日期：2016-08-08 00:00:00

abstract：:In this issue of Cancer Cell, demonstrate a novel mechanism for the oncogenic activity of MLL chimeric proteins. By providing coiled-coil or other dimerization domains, the cytoplasmic partners of MLL fusion proteins donate a platform for MLL homodimerization, allowing recruitment of accessory factors needed to activa...

journal_title：Cancer cell

authors： Hsu K,Look AT

更新日期：2003-08-01 00:00:00

abstract：:MYC is an oncogenic driver that regulates transcriptional activation and repression. Surprisingly, mechanisms by which MYC promotes malignant transformation remain unclear. We demonstrate that MYC interacts with the G9a H3K9-methyltransferase complex to control transcriptional repression. Inhibiting G9a hinders MYC ch...

journal_title：Cancer cell

authors： Tu WB,Shiah YJ,Lourenco C,Mullen PJ,Dingar D,Redel C,Tamachi A,Ba-Alawi W,Aman A,Al-Awar R,Cescon DW,Haibe-Kains B,Arrowsmith CH,Raught B,Boutros PC,Penn LZ

更新日期：2018-10-08 00:00:00

abstract：:DNA microarrays make possible the rapid and comprehensive assessment of the transcriptional activity of a cell, and as such have proven valuable in assessing the molecular contributors to biological processes and in the classification of human cancers. The major challenge in using this technology is the analysis of it...

journal_title：Cancer cell

authors： Miller LD,Long PM,Wong L,Mukherjee S,McShane LM,Liu ET

更新日期：2002-11-01 00:00:00

abstract：:Agonistic antibodies specific for members of the tumor necrosis factor receptor protein family hold great promise for immunotherapy of cancer. In this issue of Cancer Cell, White and colleagues provide evidence that the human IgG2 subclass may represent a superior backbone for the use of these antibodies in human ther...

journal_title：Cancer cell

authors： Lux A,Nimmerjahn F

更新日期：2015-01-12 00:00:00

abstract：:There is currently much interest in the idea of restoring p53 activity in tumor cells by inhibiting Hdm2/Mdm2. However, it has remained unclear whether this would also activate p53 in normal cells. Using a switchable endogenous p53 mouse model, which allows rapid and reversible toggling of p53 status between wild-type...

journal_title：Cancer cell

authors： Ringshausen I,O'Shea CC,Finch AJ,Swigart LB,Evan GI

更新日期：2006-12-01 00:00:00

abstract：:The childhood brain tumor, medulloblastoma, includes four subtypes with very different prognoses. Here, we show that paracrine signals driven by mutant β-catenin in WNT-medulloblastoma, an essentially curable form of the disease, induce an aberrant fenestrated vasculature that permits the accumulation of high levels o...

journal_title：Cancer cell

authors： Phoenix TN,Patmore DM,Boop S,Boulos N,Jacus MO,Patel YT,Roussel MF,Finkelstein D,Goumnerova L,Perreault S,Wadhwa E,Cho YJ,Stewart CF,Gilbertson RJ

更新日期：2016-04-11 00:00:00

abstract：:Solid tumors require new blood vessels for growth and metastasis, yet the biology of tumor-specific endothelial cells is poorly understood. We have isolated tumor endothelial cells from mice that spontaneously develop prostate tumors. Clonal populations of tumor endothelial cells expressed hematopoietic and mesenchyma...

journal_title：Cancer cell

authors： Dudley AC,Khan ZA,Shih SC,Kang SY,Zwaans BM,Bischoff J,Klagsbrun M

更新日期：2008-09-09 00:00:00

abstract：:Activating mutations in the FLT3 receptor tyrosine kinase occur in 30% of patients with acute myeloid leukemia. Small molecule FLT3 kinase inhibitors show selective antitumor activity in preclinical models. Clinical studies are underway. ...

journal_title：Cancer cell

authors： Sawyers CL

更新日期：2002-06-01 00:00:00

abstract：:Neuroendocrine (NE) phenotype, seen in >30% of prostate adenocarcinomas (PCa), and NE prostate tumors are implicated in aggressive prostate cancer. Formation of NE prostate tumors in the TRAMP mouse model was suppressed in mice lacking the ubiquitin ligase Siah2, which regulates HIF-1alpha availability. Cooperation be...

journal_title：Cancer cell

authors： Qi J,Nakayama K,Cardiff RD,Borowsky AD,Kaul K,Williams R,Krajewski S,Mercola D,Carpenter PM,Bowtell D,Ronai ZA

更新日期：2010-07-13 00:00:00

abstract：:Neuroblastoma is an embryonal tumor of the sympathetic nervous system and the most common extracranial tumor of childhood. By sequencing transcriptomes of low- and high-risk neuroblastomas, we detected differentially expressed annotated and nonannotated long noncoding RNAs (lncRNAs). We identified a lncRNA neuroblasto...

journal_title：Cancer cell

authors： Pandey GK,Mitra S,Subhash S,Hertwig F,Kanduri M,Mishra K,Fransson S,Ganeshram A,Mondal T,Bandaru S,Ostensson M,Akyürek LM,Abrahamsson J,Pfeifer S,Larsson E,Shi L,Peng Z,Fischer M,Martinsson T,Hedborg F,Kogner P,

更新日期：2014-11-10 00:00:00

abstract：:Emerging strategies in cancer therapeutics link the genomic mutational and proteomic landscape, allowing intelligent reasoning on target selection. In this issue of Cancer Cell, Piccinin and colleagues use this approach to demonstrate that the mesenchymal protein Twist1 inhibits p53, providing a novel target for react...

journal_title：Cancer cell

authors： Hupp TR,Hayward RL,Vojtesek B

更新日期：2012-09-11 00:00:00

abstract：:To investigate the role of signaling by the small GTPase Ral, we have generated mice deficient for RalGDS, a guanine nucleotide exchange factor that activates Ral. We show that RalGDS is dispensable for mouse development but plays a substantial role in Ras-induced oncogenesis. Lack of RalGDS results in reduced tumor i...

journal_title：Cancer cell

authors： González-García A,Pritchard CA,Paterson HF,Mavria G,Stamp G,Marshall CJ

更新日期：2005-03-01 00:00:00

abstract：:The tumor suppressor cylindromatosis (CYLD) inhibits the NFκB and mitogen-activated protein kinase (MAPK) activation pathways by deubiquitinating upstream regulatory factors. Here we show that liver-specific disruption of CYLD triggers hepatocyte cell death in the periportal area via spontaneous and chronic activation...

journal_title：Cancer cell

authors： Nikolaou K,Tsagaratou A,Eftychi C,Kollias G,Mosialos G,Talianidis I

更新日期：2012-06-12 00:00:00

abstract：:A definitive knockout reported in this issue of Cancer Cell by Sicinska et al. reveals an unsuspected role for cyclin D3 in normal T cell development and suggests new therapeutic possibilities in precursor T cell leukemia. ...

journal_title：Cancer cell

authors： Weng AP,Aster JC

更新日期：2003-12-01 00:00:00

abstract：:The budding yeast Saccharomyces cerevisiae is a genetically tractable model system with which to establish the cellular target of a given agent and investigate mechanisms of drug action. ...

journal_title：Cancer cell

authors： Bjornsti MA

更新日期：2002-10-01 00:00:00

abstract：:Van den Eynde et al. publish in this issue of Cancer Cell that metastatic colorectal cancer shows marked heterogeneity in T cell infiltration among different lesions and patients. Measurements of T cell infiltration in metastases by immunoscore offer some prognostic information and support immune editing by coevolving...

journal_title：Cancer cell

authors： de Andrea CE,Schalper KA,Sanmamed MF,Melero I

更新日期：2018-12-10 00:00:00

abstract：:Malignant astrocytomas are infiltrative and incurable brain tumors. Despite profound therapeutic implications, the identity of the cell (or cells) of origin has not been rigorously determined. We previously reported mouse models based on conditional inactivation of the human astrocytoma-relevant tumor suppressors p53,...

journal_title：Cancer cell

authors： Alcantara Llaguno S,Chen J,Kwon CH,Jackson EL,Li Y,Burns DK,Alvarez-Buylla A,Parada LF

更新日期：2009-01-06 00:00:00

abstract：:Inactivation of the von Hippel-Lindau tumor suppressor gene is linked to the development of hereditary (VHL Disease-associated) and sporadic clear cell carcinoma of the kidney. The VHL gene product, pVHL, targets the heterodimeric transcription factor HIF for polyubiquitination, and restoration of pVHL function in VHL...

journal_title：Cancer cell

authors： Kondo K,Klco J,Nakamura E,Lechpammer M,Kaelin WG Jr

更新日期：2002-04-01 00:00:00

abstract：:The TFAP2C/AP-2γ transcription factor regulates luminal breast cancer genes, and loss of TFAP2C induces epithelial-mesenchymal transition. By contrast, the highly homologous family member, TFAP2A, lacks transcriptional activity at luminal gene promoters. A detailed structure-function analysis identified that sumoylati...

journal_title：Cancer cell

authors： Bogachek MV,Chen Y,Kulak MV,Woodfield GW,Cyr AR,Park JM,Spanheimer PM,Li Y,Li T,Weigel RJ

更新日期：2014-06-16 00:00:00

abstract：:Overexpression of Bcl-xL, loss of p19 ARF, and loss of p53 all accelerate Myc oncogenesis. All three lesions are implicated in suppressing Myc-induced apoptosis, suggesting that this is a common mechanism by which they synergize with Myc. However, using an acutely switchable model of Myc-induced tumorigenesis, we demo...

journal_title：Cancer cell

authors： Finch A,Prescott J,Shchors K,Hunt A,Soucek L,Dansen TB,Swigart LB,Evan GI

更新日期：2006-08-01 00:00:00

abstract：:Activation of the MLL-ENL-ERtm oncogene initiates aberrant proliferation of myeloid progenitors. Here, we show induction of a fail-safe mechanism mediated by the DNA damage response (DDR) machinery that results in activation of the ATR/ATM-Chk1/Chk2-p53/p21(CIP1) checkpoint and cellular senescence at early stages of c...

journal_title：Cancer cell

authors： Takacova S,Slany R,Bartkova J,Stranecky V,Dolezel P,Luzna P,Bartek J,Divoky V

更新日期：2012-04-17 00:00:00

abstract：:The erythroleukemia developed by spi-1/PU.1 transgenic mice is a multistage process characterized by an early arrest of the proerythroblast differentiation followed later on by malignant transformation. Herein, we report the presence of acquired mutations in the SCF receptor gene (Kit) in 86% of tumors isolated during...

journal_title：Cancer cell

authors： Kosmider O,Denis N,Lacout C,Vainchenker W,Dubreuil P,Moreau-Gachelin F

更新日期：2005-12-01 00:00:00

abstract：:The genetic mechanisms responsible for increased incidence of lymphoma in immunocompromised individuals have not been fully elucidated. We show that, in a line of TCR transgenic TG-B mice, an insertional mutation in one allele of the Epm2a locus and epigenetic silencing of another led to a high rate of lymphoma with e...

journal_title：Cancer cell

authors： Wang Y,Liu Y,Wu C,Zhang H,Zheng X,Zheng Z,Geiger TL,Nuovo GJ,Liu Y,Zheng P

更新日期：2006-09-01 00:00:00

abstract：:Adaptive immune resistance ablates effective anti-tumor immune responses. In a recent issue of Nature, Victor and colleagues describe that anti-PD-L1 combats adaptive immune resistance upon localized radiation plus anti-CTLA-4 therapy. The superior activity of radiation and dual immune checkpoint blockade is mediated ...

journal_title：Cancer cell

authors： Ngiow SF,McArthur GA,Smyth MJ

更新日期：2015-04-13 00:00:00

abstract：:The life history of cancer cells encompasses a series of genetic missteps in which normal cells are progressively transformed into tumor cells that invade surrounding tissues and become malignant. Most prominent among the regulators disrupted in cancer cells are two tumor suppressors, the retinoblastoma protein (RB) a...

journal_title：Cancer cell

authors： Sherr CJ,McCormick F

更新日期：2002-08-01 00:00:00